In a statement, CVS Chief Executive David Joyner highlighted "a significant and durable recovery" at Aetna, and "strong retention" at CVS Caremark. Last quarter, CVS said that Aetna is exiting the ...

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

A high-level overview of Bollinger Innovations Inc. (BINI) stock. View (BINI) real-time stock price, chart, news, analysis, analyst reviews and more.